HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

NCT05883748 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ENROLLING_BY_INVITATION

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Erythropoietic Protoporphyria

Interventions

DRUG: DISC-1459
DRUG: DISC-1459

Sponsor

Disc Medicine, Inc